Navigation Links
Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
Date:4/3/2011

a composite of death, myocardial infarction (MI), urgent target vessel revascularization (TVR) or recurrent ischemia at 30 days.  

Previously presented data from RADAR (AHA, November 2010) confirmed that pegnivacogin dosed at 1mg/kg reproducibly resulted in near complete inhibition of FIXa in an ACS population.  The latest RADAR results showed that ACUITY major bleeding following immediate sheath removal exhibited a dose response with bleeding rates decreasing with increasing levels of reversal.  Rates of bleeding were lower in the 75% and 100% reversal arms than heparin.  In addition, the incidence of ischemic events was lower in REG1 treated patients compared with those treated with heparin.  

Adverse events (AEs) other than bleeding and ischemic events were rare and evenly distributed among the arms of the study.  Three patients, clustered late in the trial and in Europe, had allergic-like reactions shortly after receiving pegnivacogin.  Characterization of these reactions is ongoing.  

"We are thrilled by the results of RADAR and the groundbreaking advance in anticoagulant therapy that they foretell.  It is now clear that control matters.  REG1 uniquely has shown the promise of simultaneously reducing ischemia and bleeding in comparison to heparin," said Dr. David J. Mazzo, President and CEO of Regado Biosciences, Inc.  He added, "The results of the RADAR trial solidly support Phase 3 development of REG1 in the broader ACS population.  Regado plans to move forward in this indication as well as in a parallel indication of open heart surgery."  

"The Phase 2b RADAR results suggest that high intensity FIXa inhibition with active control may ultimately represent a potential treatment option for addressing both ischemic and bleeding endpoints for patients who require short term anticoagulation in acute care settings," said John H. Alexander, MD, MHS, FACC of the Duke Clinica
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
2. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
3. Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City
4. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
5. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
6. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
7. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
8. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
9. Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
10. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
11. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)...  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO )("NW Bio"), a ... and inoperable solid tumor cancers, announced today that CEO ... Annual Phacilitate Immunotherapy Forum in Washington D.C. ... place on January 26 at 10:30 a.m. EST at the ...
(Date:1/23/2015)... a third of reproductive-aged women enrolled in Medicaid, and more ... prescription for an opioid pain medication each year during 2008-2012, ... Weekly Report (MMWR). Opioids are typically prescribed ... They are also found in some prescription cough medications. The ...
(Date:1/23/2015)... NEW YORK , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer ... the board of directors of Advaxis, Inc. ("Advaxis" or ... the board has breached its fiduciary duties to shareholders. ... published on an investing website reporting that Advaxis had ...
Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2
... , , , , , , ... SMA ), a leading independent provider of products to ... today a restructuring that includes a facility consolidation and other ... cost savings. The restructuring is designed to position the Company ...
... , ATLANTA, Dec. ... lesions too close to critical anatomy and those with multiple ... a new "frameless" device for use with Leksell Gamma ... of Virginia Health System (UVA) clinicians to non-invasively fix or ...
Cached Medicine Technology:Symmetry Medical Announces Restructuring 2Symmetry Medical Announces Restructuring 3Symmetry Medical Announces Restructuring 4University of Virginia Acquires New Elekta Technology to Expand Patient Groups That Could Benefit From Gamma Knife Surgery 2University of Virginia Acquires New Elekta Technology to Expand Patient Groups That Could Benefit From Gamma Knife Surgery 3
(Date:1/22/2015)... LunaDress, with its top dressmaking technologies, has ... the business is showing its latest designs of wedding dresses ... to the company’s CEO, all the fresh new products are ... discounts, up to 80% off. All the clothes from LunaDress ...
(Date:1/22/2015)... Woodloch Pines, an all-inclusive family resort ... as the number one best large hotel for families in ... for their annual Travelers’ Choice Awards. , TripAdvisor represents ... is home to millions of unbiased and honest traveler reviews. ...
(Date:1/22/2015)... AZ (PRWEB) January 22, 2015 Padre Murphy's ... long supporter of Pro Player Health Alliance (PPHA). ... Padre Murphy's in getting everyone, including NFL greats, treated for ... of the leading groups supporting the cause in the valley. ...
(Date:1/22/2015)... TX (PRWEB) January 22, 2015 The Incredible ... Bodybuilder Ben Pakulski to increase lean muscle by up to ... has caught the attention of HealthyandFitZone.com’s Stan Stevenson, prompting an ... that it is a step-by-step, scientific diet formula that allows ...
(Date:1/22/2015)... January 22, 2015 Blue Cross and Blue ... who exemplify what it means to “Live Fearless.” ... people to share their stories about how they or someone ... inspired others by living in the moment. By telling these ...
Breaking Medicine News(10 mins):Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2
... UTC Power, a United,Technologies Corp. (NYSE: UTX ) ... California,s Napa Valley with its new, next-generation,fuel cell, the ... in the summer of 2009., St. Helena Hospital ... Health, a not-for-profit health care system operating in,California, Hawaii, ...
... /Xinhua-PRNewswire/ -- The first batch of imported food,( ... in,preparation for the Olympic Games has arrived. The ... port in Shanghai on June 18. To ensure ... and Quarantine Bureau,took great care in their preparations ...
... chronic back pain. This was the result of ... Zimmermann-Stenzel and her colleagues and published in the ... (Dtsch Arztebl Int, 2008; 105[24]: 441-8). , ... Institute interviewed more than 8000 private persons in ...
... had higher cholesterol, blood fats into adulthood, British study ... an unhealthy diet during pregnancy may raise your child,s ... sugar levels, British researchers report. , In tests on ... of females a diet of processed junk food such ...
... marketing promotional products company, is tapped in to a network of ... , ... Lewiston, ME (PRWEB) July 1, 2008 -- ... its Web site, Crestline Custom Imprinted Products, a direct marketing ...
... ARLINGTON, Va., July 1 The following is a,statement ... is grateful that Congress has taken the authority and ... Management,(TCM) rules, as well as four other controversial rules ... appropriations bill. By doing,so, Congress has a made a ...
Cached Medicine News:Health News:St. Helena's Hospital Orders New Model 400kW Fuel Cell From UTC Power 2Health News:China Improves Safety Management on Imported Foods in Preparation for Olympic Games 2Health News:Mom's Unhealthy Diet May Have Long-Term Impact on Baby 2Health News:Crestline Has Access to Hundreds of Thousands of Items 2Health News:Statement by Christine James-Brown, President and CEO, Child Welfare League of America (CWLA) Re: Moratorium on Medicaid Regulations 2
Soft Non-Latex, Adjustable Flange Nasopharyngeal Airway. Pediatric sizes available. Non-Latex Mediprene material with soft elastic finish. Adjustable flange for a better fit and increased patient com...
Soft Guedel Oral Airways...
All oral and nasal airways are manufactured with smooth, rounded edges for increased patient comfort and safety., ,Portex® offers a broad selection of airways for a variety of clinical applicati...
... Rapid intubation of difficult airways., ... time and accuracy are critical. Now you ... effective ventilation with the Combitube®: Esophageal/Tracheal double-Lumen ... the Combitube airway is designed to establish ...
Medicine Products: